Request Demo

Last update 08 May 2025

PDGFRB-Associated Chronic Eosinophilic Leukemia

Last update 08 May 2025

Basic Info

Synonyms

Atypical Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myeloproliferative Disorder with Eosinophilia, Clonal Eosinophilia with Chronic Myeloproliferative Disorder

+ [3]

Introduction-

Drugs associated with PDGFRB-Associated Chronic Eosinophilic Leukemia

CHMFL-PDGFR-159

Target

PDGFRα

Mechanism

PDGFRα inhibitors

Active Org.-

Originator Org.

Hefei Institutes of Physical Science

Active Indication-

Inactive Indication

PDGFRB-Associated Chronic Eosinophilic Leukemia

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with PDGFRB-Associated Chronic Eosinophilic Leukemia

100 Translational Medicine associated with PDGFRB-Associated Chronic Eosinophilic Leukemia

0 Patents (Medical) associated with PDGFRB-Associated Chronic Eosinophilic Leukemia

Literatures (Medical) associated with PDGFRB-Associated Chronic Eosinophilic Leukemia

24 Feb 2025·Cureus

Chronic Eosinophilic Leukemia Positive for FIP1L1-PDGFRa

Article

Author: Caucci, Stephen ; Haydon, Steven J ; Hrinczenko, Borys ; Clark, Shane ; Ross, Danielle E

FIP1L1-PDGFRα-positive chronic eosinophilic leukemia (CEL) is a rare subtype of myeloproliferative neoplasm characterized by organ damage caused by eosinophilic granules containing cytokines and humoral factors. These include interleukin-5 (IL-5), interleukin-4 (IL-4), and interleukin-13 (IL-13). We present a case study of a 71-year-old male who initially presented with cough, fever, night sweats, and weight loss. Fluorescence in situ hybridization (FISH) and cytogenetic testing confirmed that the patient had FIP1L1-PDGFRα-positive chronic eosinophilic leukemia. Treatment with imatinib and prednisone led to a rapid decrease in the eosinophil count without further damage from eosinophilic infiltration. Our patient has tolerated therapy with occasional lightheadedness that he attributed to external factors, and he continues to remain in remission. This case study aims to contribute to the existing knowledge regarding the discovery and treatment of this disease.

19 Mar 2024·Gaceta Médica de México

Essential thrombocythaemia

Article

Author: Zapata-Canto, Nidia ; Martínez-Ramírez, Mario Alberto ; Rojas-Castillejos, Flavio ; García-Castillo, Carolina ; Espinosa-Partida, Arturo ; Aguilar-Hidalgo, José Antonio ; Pérez-Zúñiga, Juan Manuel ; Aguilar-Luévano, Jocelyn ; Herrera-Olivares, Wilfrido ; Mójica-Balderas, Liliana ; Cano-León, Ana Ma de la Luz ; Saucedo-Montes, Erick Eduardo ; Barragán-Ibáñez, Gabriel ; García-Camacho, Alinka Socorro ; Morales-Adrián, Javier ; Díaz-Ramírez, Hugo Francisco ; Milán-Salvatierra, Andrea Iracema ; Romero-Martínez, Eduardo ; Meillón-García, Luis Antonio ; Pérez-Gómez, Karen Daniela ; Tapia-Enríquez, Ana Laura ; Bates-Martín, Ramón Alberto ; López-Salazar, Javier ; Espitia-Ríos, Ma Eugenia ; López-Arroyo, José Luis ; Alcívar-Cedeño, Luisa Ma ; Galaz-Cordero, Lourdes Elena ; Salazar-Ramírez, Óscar ; McNally-Guillén, Bosco Martín ; Gómez-Cortés, Sue Cynthia ; Moralws-Hernández, Alba Edna ; Olarte-Carrillo, Irma ; Martínez-Castro, Raúl ; Barbosa, Diego ; Hernández-Caballero, Álvaro ; Romero-Rodelo, Hilda ; Pérez, Fernando Jacobo ; Vilchis-González, Shendel Paulina ; Estrada-Domínguez, Patricia ; Ventura-Enríquez, Yanet ; Álvarez-Vera, José Luis ; Guerra-Alarcón, Lidia Virginia ; Barranco-Lampón, Gilberto ; Soriano-Mercedes, Emely Johanny ; Ángeles Rosales-López, Ma de Los ; Garzón-Velásquez, Katheryn Betsabé ; Ruiz-Contreras, Josué Isel ; Acosta-Maldonado, Brenda Lizeth ; Zazueta-Pozos, Juan Francisco ; Alvarado-Ibarra, Martha ; Pacheco, Martín Jacobo ; Campa-Monroy, Dafne Itzel ; Vivas-Arteaga, Cindy Lissette ; Cota-Rangel, Xóchitl ; Arana-Luna, Luara ; Báez-Islas, Pamela Elena ; Mújica-Martínez, Aldo ; Peña-Celaya, José Antonio de la ; Urbina-Escalante, Elizabeth ; Medina-Coral, Jesús Emanuel ; Hernández-Ruiz, Eleazar ; Flores-Ordúñez, Karen ; Banda-García, Luisa Iztacihuatl ; Loera-Fragoso, Sergio José ; Neme-Yunes, Yvette ; Martínez-Coronel, Jorge ; Carballo-Zarate, Adrián Alejandro ; Pérez-Lizardi, Alejandra Betsabé ; Ramírez-Hoyos, Paulina ; Martínez, Adolfo ; Anaya-Cuéllar, Irene ; Delgado-López, Nancy ; Minamy, Jaime Israel-García ; Navarrete, Juan José ; Aguilar-Andrade, Carolina ; Tepepa-Flores, Fredy ; Jiménez-Ochoa, Marco Alejandro ; Peñaloza-Ramírez, Rosalinda ; Rodríguez-Sánchez, Vania ; Aguirre-Reyes, Oyuky Gissell

Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis in peripheral blood and an increase in the number of mature megakaryocytes in the bone marrow. In addition to marked thrombocytosis, it is characterized by increased thrombotic or hemorrhagic risk and the presence of constitutional symptoms. Patients with ET have a low but known risk of disease progression to myelofibrosis and/or acute leukemia. The diagnosis is made based on the 2016 WHO criteria. At present, available treatments for patients with ET are mainly aimed at minimizing the risk of thrombosis and/or bleeding.

01 Apr 2023·Current Cancer Drug Targets

Impact of GSTT1 and GSTM1 Polymorphisms in the Susceptibility to Philadelphia Negative Chronic Myeloid Leukaemia

Article

Author: Tebien, Entesar M. ; Elderdery, Abozer Y. ; Mills, Jeremy ; Omer, Nawal Eltayeb ; Suliman, Bandar A. ; Idris, Hadeil M.E. ; Alhamidi, Abdulaziz H. ; Diab, Nada Abdalfatah ; Hamza, Siddiqa M.A.

Materials and Methods:We report on a case-control study with 126 participants, divided into 26 patients with Ph-ve CML (57.7% male, 42.3% female) and 100 healthy volunteers (51% male, 49% female) with no medical history of cancer as a control population. All Ph-ve CML patients were diagnosed according to standard hematologic and cytogenetic criteria based on CBC, confirmed by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) to determine the presence or absence of the BCRABL gene, followed by bone marrow (BM) examination.Background:Our research aimed to clarify the role of genetic polymorphisms in GST (T1 and M1) in the development of Ph-ve CML.Results:Of the 26 studied cases, 50% had the GSTT1 null genotype against 21% of the control group, a statistically significant difference (CI= 1.519 - 9.317; p-value= 0.004). The GSTM1 null genotype was detected in 23.1% of cases and 35% of controls, a difference not statistically significant (OR= 0.557; CI= 0.205-1.515; p-value= 0.252). The distribution of GSTT1 and GSTM1 polymorphisms was also examined according to gender, age and ethnic grouping; these findings revealed no statistically significant differences.Conclusion:Our study reveals a strong correlation between GSTT1 polymorphism and Ph-ve CML, whereas the data for GSTM1 polymorphisms indicates no role in the initial development of the disease. More studies are required to further clarify these and other genes' roles in disease development.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PDGFRB-Associated Chronic Eosinophilic Leukemia

Basic Info

Related

Analysis